{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:00:14Z","timestamp":1760522414319},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,11,25]],"date-time":"2005-11-25T00:00:00Z","timestamp":1132876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s00280-005-0136-y","type":"journal-article","created":{"date-parts":[[2005,11,24]],"date-time":"2005-11-24T13:52:40Z","timestamp":1132840360000},"page":"35-39","source":"Crossref","is-referenced-by-count":53,"title":["CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas"],"prefix":"10.1007","volume":"58","author":[{"given":"Jong Gwang","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Soo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Ho","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Bo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ik-Joo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Don","family":"Joo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hak","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,25]]},"reference":[{"key":"136_CR1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199211053271903","volume":"327","author":"LI Gordon","year":"1992","unstructured":"Gordon LI, Harrington D, Anderson J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A (1992) Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin\u2019s lymphoma. N Engl J Med 327:1342\u20131349","journal-title":"N Engl J Med"},{"key":"136_CR2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med 328:1002\u20131006","journal-title":"N Engl J Med"},{"key":"136_CR3","first-page":"809","volume":"30","author":"CH Lee","year":"1998","unstructured":"Lee CH, Im YH, Ryoo BY, Nam SM, Kim MS, Lee YS, Oh KK, Shim YS, Yoo SY, Lee JO, Kang TW, Kang YK (1998) Primary CHOP chemotherapy followed by involved field radiation therapy in clinical stage I or II aggressive non-Hodgkin\u2019s lymphomas. Cancer Res Treat 30:809\u2013817","journal-title":"Cancer Res Treat"},{"key":"136_CR4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma study group. Blood 84:1361\u20131392","journal-title":"Blood"},{"key":"136_CR5","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","volume":"89","author":"A Melnyk","year":"1997","unstructured":"Melnyk A, Rodrguez A, Pugh WC, Cabannillas F (1997). Evaluation of the revised European\u2013American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin\u2019s lymphoma. Blood 89:4514\u20134520","journal-title":"Blood"},{"key":"136_CR6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"key":"136_CR7","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 23:4117\u20134126","journal-title":"J Clin Oncol"},{"key":"136_CR8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/bjc.1989.224","volume":"60","author":"H Koppler","year":"1989","unstructured":"Koppler H, Pfluger KH, Eschenbach I, Pfab R, Lennert K, Wellens W, Schmidt M, Gassel WD, Kolb T, Hassler R (1989) CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin\u2019s lymphoma: a phase II multicenter study. Br J cancer 60:79\u201382","journal-title":"Br J cancer"},{"key":"136_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428199609045720","volume":"24","author":"T Karakas","year":"1996","unstructured":"Karakas T, Bergmann L, Stutte HJ, Jager E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D (1996) Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk lymphoma 24:121\u2013129","journal-title":"Leuk lymphoma"},{"key":"136_CR10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin\u2019s lymphoma. Cancer 101:1835\u20131842","journal-title":"Cancer"},{"key":"136_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","volume":"113","author":"S Sallah","year":"2001","unstructured":"Sallah S, Wan JY, Nguyen NP (2001) Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113:185\u2013187","journal-title":"Br J Haematol"},{"key":"136_CR12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:1244\u20131253","journal-title":"J Clin Oncol"},{"key":"136_CR13","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic singnificance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Blood 92:76\u201382","journal-title":"Blood"},{"key":"136_CR14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0959-8049(01)00344-6","volume":"38","author":"K Kim","year":"2002","unstructured":"Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European\u2013American lymphoma (REAL) classification. Eur J Cancer 38:75\u201381","journal-title":"Eur J Cancer"},{"key":"136_CR15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreudnschuh","year":"2004","unstructured":"Pfreudnschuh M, Trumper L, Kloess M, Schmits r, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626\u2013633","journal-title":"Blood"},{"key":"136_CR16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","volume":"9","author":"PL Zinzani","year":"1998","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni f, Albertini P (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351\u20131353","journal-title":"Ann Oncol"},{"key":"136_CR17","first-page":"3","volume":"23","author":"W Plunkett","year":"1996","unstructured":"Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23:3\u201315","journal-title":"Semin Oncol"},{"key":"136_CR18","first-page":"4024","volume":"48","author":"V Heinemann","year":"1988","unstructured":"Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2\u2019,2\u2019-difluorodeoxycytidine and 1-beta-D-arabinofuranosyl-cytosine. Cancer Res 48:4024\u20134031","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0136-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-005-0136-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0136-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T05:33:35Z","timestamp":1586583215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-005-0136-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1007\/s00280-005-0136-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,25]]}}}